Rhumatologie

Cost-Effectiveness of Two Therapeutic Regimens of Infliximab in Ankylosing Spondylitis: Economic Evaluation Within a Randomized Controlled Trial

Annals of the Rheumatic Diseases – Concise report – 2009 Bruno Fautrel, Mathilde Benhamou, Maxime Breban, Carine Roy, Christelle Lenoir, Gérard Trape, Alain Baleydier, Philippe Ravaud, Maxime Dougados

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France
Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL
Rhumatologie

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL

Treat to target in axial spondyloarthritis: From its concept to its implementation
Rhumatologie

Treat to target in axial spondyloarthritis: From its concept to its implementation